Form4insider filings, from the source

SEC Form 3 · accession 0001209191-18-038845

Kezar Life Sciences, Inc. · KZR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
John Franklin Fowler
Officer — CEO · Director
Period of report
Jun 20, 2018
Accepted (ET)
Jun 20, 2018 · 5:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645666

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stockholding———292,704D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Employee Stock Option (Right to Buy)F1$0.90holding————Sep 9, 2025Common Stock156,421—D
Employee Stock Option (Right to Buy)F2$1.41holding————Sep 14, 2026Common Stock48,932—D
Employee Stock Option (Right to Buy)F3$2.37holding————Oct 9, 2027Common Stock177,935—D
Employee Stock Option (Right to Buy)F4$2.37holding————Jan 6, 2028Common Stock88,967—D
Employee Stock Option (Right to Buy)F5$5.91holding————Apr 15, 2028Common Stock133,451—D

Explanation of responses